DMC Group LLC Has $407,000 Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

DMC Group LLC lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,261 shares of the biotechnology company’s stock after selling 136 shares during the period. DMC Group LLC’s holdings in Sarepta Therapeutics were worth $407,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SRPT. Blue Trust Inc. boosted its position in shares of Sarepta Therapeutics by 896.5% in the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 511 shares during the period. VitalStone Financial LLC bought a new stake in Sarepta Therapeutics in the 3rd quarter valued at $327,000. UMB Bank n.a. boosted its holdings in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares during the period. Connective Portfolio Management LLC acquired a new stake in Sarepta Therapeutics in the 3rd quarter worth $1,624,000. Finally, Handelsbanken Fonder AB increased its holdings in shares of Sarepta Therapeutics by 12.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 23,815 shares of the biotechnology company’s stock worth $2,974,000 after purchasing an additional 2,600 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 2.3 %

Shares of SRPT opened at $127.08 on Friday. The company has a market capitalization of $12.01 billion, a P/E ratio of 1,155.27 and a beta of 0.82. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25. The business’s 50 day simple moving average is $129.00 and its 200-day simple moving average is $132.36. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business’s revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SRPT has been the subject of several research reports. BMO Capital Markets increased their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. UBS Group lifted their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Leerink Partners boosted their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $183.89.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.